Prevention of Postoperative Delirium With Donepezil

Patients undergoing hip or knee joint replacement at the age of 70 years or above who are cognitively unimpaired will receive donepezil or matching placebo before (over 5-7 days), during and after (over 7 days) surgery. The incidence of delirium will be monitored at 3 days, 7 days, and 49 days following surgery. We hypothesize that the incidence of delirium can be lowered from 20 per cent to 10 per cent by the intervention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitively Normal Elderly Individuals Confusion Delirium Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

70 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Deps. of Psychiatry and Anaesthesiology, Tech. Universitaet Munich

Munich, D-81675, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cognitively healthy, elective hip or knee replacement

Exclusion criteria

Ongoing cholinergic treatment, dementia, delirium, acute physical illness

Treatment and study plan

Donepezil

Drug

Primary outcomes

Incidence of delirium

Secondary outcomes

Cognitive performance

Sponsors and collaborators

Lead sponsor

Technical University of Munich

Other

Collaborators

Eisai Deutschland

Registry information

Important dates

Study start: 2006
Study completion: 2009
First posted: Sep 22, 2005
Registry last updated: Sep 14, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed